Phone:| Tech Support:| E-mail:
Home > Products > Life sciences > Enzymes and proteins > Dihydrofolate Reductase human

Dihydrofolate Reductase human

Product #: S0157
Image SKU-Pack Size Stock Price($) Quantity

Documents

Details

l General Information

Product Name

Dihydrofolate Reductase human

General deion

Human DHFR is an 186 amino acid protein with an apparent molecular weight of 25 kDa. It is 30% homologous to the E. coli protein and up to 70% homologous to vertebrate proteins.

Synonym

DHFR, Tetrahydrofolate NADP+ oxidoreductase

Assay

≥80% (SDS-PAGE), recombinant, expressed in E. coli, ≥1 units/mg protein

concentration

0.02-0.06 mg/mL

MDL number

MFCD00130955

Suitability

BioReagent

l Physical and Chemical Information

Appearance

Colorless glycerin solution

Physical form

Solution in 10 mM Tris pH 8, 1 mM EDTA, 0.5 mM DTT, 5 μM NADPH, protease inhibitors, and 50% glycerol.

l Biological Information

Biochem/Physiol Actions

Km5,6

NADPH 0.16 mM

7,8-dihydrofolate 0.03 mM

8-methylpterin 0.13 mM

Ki7

Folate 2.6x10-5 mM

Methotrexate 6.1-9x10-9

The human DHFR gene, as well as DHFR genes in other mammalian species, overcome the inhibitory effects of methotrexate by a mechanism of gene amplification or by amino-acid mutagenesis. Dihydroflate reductase (DHFR) catalyzes the NADPH dependent reduction of dihydrofolate (DHF) to tetrahydrofolate (THF) and, at a much lower rate, the conversion of folate to THF. The reaction product, THF, is an essential cofactor in the conversion of deoxyuridylate (dUMP) to deoxythymidylate (dTMP) by thymidylate synthetase. It is a key enzyme in thymidine synthesis. Therefore, DHFR is a critical enzyme in DNA synthesis and has become a target for drug development and cancer therapy. The variations between DHFR from different sources have enabled the development of species selective DHFR inhibitors, such as trimethoprim (antibacterial and antifungal), pyrimethamine (antiprotozoal), and methotrexate; MTX (antineoplastic, antipsoriatic, and anti-inflammatory).

Application

Dihydrofolate reductase (DHFR) is a key enzyme in thymidine synthesis. It catalyzes the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF). At a much lower rate, it catayzes the conversion of folate to THF. Since thymidine is a necessary substrate for DNA synthesis, DHFR is a target for anticancer drug development. Methotrexate is the prototype dihydrofolate reductase inhibitor. The enzyme from Sigma has been used in the inhibitory studies of Leishmaniasis donovani pteridine reductase 1 (PTR1). The enzyme has also been used as a positive control to measure the DHFR activity of a protein, MS0308, purified from Mycobacterium smegmatis. Human dihydrofolate reductase has been used in a study to investigate the stable  of green fluorescent protein and the targeted disruption of thioredoxin peroxidase-1 gene in Babesia bovis. Human dihydrofolate reductase has also been used in a study to investigate the structural analysis of human dihydrofolate reductase as a binary complex.

Unit Definition

One unit will convert 1.0 μmole of dihydrofolic acid to tetrahydrofolic acid in 1 minute at pH 7.5 at 22 °C.

l Packaging & Storage

Storage temp.

-20°C

l Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses.

l References

1. http://www.drugbank.ca

2. https://ncit.nci.nih.gov

3. https://www.ncbi.nlm.nih.gov

天问科技